PURPOSE: This study aimed to determine the dose effect of smoking on the mutational frequency and spectrum of epidermal growth factor receptor (EGFR) gene in Korean non-small cell lung cancer (NSCLC). METHODS: Detailed smoking histories were obtained from 324 consecutively enrolled Korean NSCLC patients. Mutational status of EGFR (exon 18-21) was determined using nested polymerase chain reaction amplification. RESULTS: A total of 108 EGFR mutations (33.3%) were identified in 107 patients. Decreased EGFR mutation rate with increased smoking dose was observed, with 48.0% (82 of 171) in never smokers, 23.1% (15 of 65) in former smokers, and 11.4% (10 of 88) in current smokers. The incidence of EGFR mutation was significantly lower in patients who smoked for more than 25 pack-years (P < 0.0001) or who stopped smoking cigarettes less than 10 years ago (P < 0.0001). Mutations in exon 19 or 21 were associated with fewer total smoke years (5.0 vs. 25.0 years in exon 20, P = 0.024), fewer total pack-years (6.3 vs. 38.9 pack-years in exon 20, P = 0.079), and more smoke-free years (11.1 vs. 3.6 years in exon 20, P = 0.027), compared with those in exon 20. Mutations in exon 19 or 21 were associated with female (P < 0.0001), never smoker (P < 0.0001), and adenocarcinoma (P < 0.0001), whereas those in exon 20 were not. CONCLUSIONS: Smoking dosage affects the incidence of EGFR mutations. EGFR mutations in exon 19 or 21 are associated with low exposure to cigarette smoke, whereas EGFR mutation in exon 20 is more common in smokers.
PURPOSE: This study aimed to determine the dose effect of smoking on the mutational frequency and spectrum of epidermal growth factor receptor (EGFR) gene in Korean non-small cell lung cancer (NSCLC). METHODS: Detailed smoking histories were obtained from 324 consecutively enrolled Korean NSCLCpatients. Mutational status of EGFR (exon 18-21) was determined using nested polymerase chain reaction amplification. RESULTS: A total of 108 EGFR mutations (33.3%) were identified in 107 patients. Decreased EGFR mutation rate with increased smoking dose was observed, with 48.0% (82 of 171) in never smokers, 23.1% (15 of 65) in former smokers, and 11.4% (10 of 88) in current smokers. The incidence of EGFR mutation was significantly lower in patients who smoked for more than 25 pack-years (P < 0.0001) or who stopped smoking cigarettes less than 10 years ago (P < 0.0001). Mutations in exon 19 or 21 were associated with fewer total smoke years (5.0 vs. 25.0 years in exon 20, P = 0.024), fewer total pack-years (6.3 vs. 38.9 pack-years in exon 20, P = 0.079), and more smoke-free years (11.1 vs. 3.6 years in exon 20, P = 0.027), compared with those in exon 20. Mutations in exon 19 or 21 were associated with female (P < 0.0001), never smoker (P < 0.0001), and adenocarcinoma (P < 0.0001), whereas those in exon 20 were not. CONCLUSIONS: Smoking dosage affects the incidence of EGFR mutations. EGFR mutations in exon 19 or 21 are associated with low exposure to cigarette smoke, whereas EGFR mutation in exon 20 is more common in smokers.
Authors: Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245
Authors: DuyKhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Ennapadam S Venkatraman; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch Journal: J Clin Oncol Date: 2006-02-27 Impact factor: 44.544
Authors: Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard Journal: Lancet Date: 2008-11-22 Impact factor: 79.321
Authors: Heidi Greulich; Tzu-Hsiu Chen; Whei Feng; Pasi A Jänne; James V Alvarez; Mauro Zappaterra; Sara E Bulmer; David A Frank; William C Hahn; William R Sellers; Matthew Meyerson Journal: PLoS Med Date: 2005-10-04 Impact factor: 11.069
Authors: K Sugio; H Uramoto; K Ono; T Oyama; T Hanagiri; M Sugaya; Y Ichiki; T So; S Nakata; M Morita; K Yasumoto Journal: Br J Cancer Date: 2006-03-27 Impact factor: 7.640
Authors: Snjezana Dogan; Ronglai Shen; Daphne C Ang; Melissa L Johnson; Sandra P D'Angelo; Paul K Paik; Edyta B Brzostowski; Gregory J Riely; Mark G Kris; Maureen F Zakowski; Marc Ladanyi Journal: Clin Cancer Res Date: 2012-09-26 Impact factor: 12.531
Authors: M Beau-Faller; N Prim; A-M Ruppert; I Nanni-Metéllus; R Lacave; L Lacroix; F Escande; S Lizard; J-L Pretet; I Rouquette; P de Crémoux; J Solassol; F de Fraipont; I Bièche; A Cayre; E Favre-Guillevin; P Tomasini; M Wislez; B Besse; M Legrain; A-C Voegeli; L Baudrin; F Morin; G Zalcman; E Quoix; H Blons; J Cadranel Journal: Ann Oncol Date: 2013-11-26 Impact factor: 32.976
Authors: M Talikka; N Sierro; N V Ivanov; N Chaudhary; M J Peck; J Hoeng; C R E Coggins; M C Peitsch Journal: Crit Rev Toxicol Date: 2012-09-18 Impact factor: 5.635